Free Trial

Structure Therapeutics (GPCR) 10K Form and Latest SEC Filings 2026

Structure Therapeutics logo
$41.10 -1.94 (-4.51%)
Closing price 04:00 PM Eastern
Extended Trading
$41.70 +0.60 (+1.46%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Structure Therapeutics SEC Filings & Recent Activity

Structure Therapeutics (NASDAQ:GPCR) has submitted 185+ documents to the U.S. Securities and Exchange Commission (SEC) since 2023. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Structure Therapeutics's financial statements. The most recent filing was a Form ARS submitted on April 23, 2026.

Form 4
Structure Therapeutics Inc. Reports Ownership Change on Apr. 23, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Structure Therapeutics Files Current Report on Apr. 15, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Structure Therapeutics Files Quarterly Report on Nov. 6, 2025

The 10-Q contains Structure Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Structure Therapeutics SEC Filing History

Browse Structure Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/23/2026 3:30 PM
Structure Therapeutics (1888886) Filer
Form DEF 14A
04/23/2026 3:35 PM
Structure Therapeutics (1888886) Filer
Form ARS
04/23/2026 3:19 PM
Lang Matthew (1712069) Reporting
Structure Therapeutics (1888886) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/23/2026 3:21 PM
Lang Matthew (1712069) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/16/2026 1:17 PM
FMR LLC (315066) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:05 AM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/23/2026 3:30 PM
Stevens Raymond C (1698149) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:30 PM
Structure Therapeutics (1888886) Issuer
Yoon Jun (1962414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:30 PM
Lin Xichen (1962926) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:30 PM
Ma Yingli (1963664) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:30 PM
Coll Crespo Blas (2037144) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/23/2026 3:30 PM
Hall Ashley (1801842) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 7:01 AM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 5:20 PM
Stevens Raymond C (1698149) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:20 PM
Hall Ashley (1801842) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:20 PM
Structure Therapeutics (1888886) Issuer
Yoon Jun (1962414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:20 PM
Lin Xichen (1962926) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:20 PM
Ma Yingli (1963664) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:20 PM
Coll Crespo Blas (2037144) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 4:22 PM
Structure Therapeutics (1888886) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/26/2026 3:11 PM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2026 7:46 AM
Deep Track Capital, LP (1856083) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
02/10/2026 10:23 AM
Structure Therapeutics (1888886) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
02/05/2026 12:40 PM
FMR LLC (315066) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
01/20/2026 8:22 AM
FMR LLC (315066) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 3:07 PM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2025 4:04 PM
Structure Therapeutics (1888886) Filer
Form 424B5
12/10/2025 4:06 PM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2025 1:07 PM
FMR LLC (315066) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 4:28 PM
Structure Therapeutics (1888886) Filer
Form 424B5
12/08/2025 7:47 AM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 8:01 AM
Avoro Capital Advisors LLC (1633313) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G
11/14/2025 7:15 AM
Deep Track Capital, LP (1856083) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
11/07/2025 7:18 AM
Structure Therapeutics (1888886) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
11/07/2025 7:16 AM
Structure Therapeutics (1888886) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
11/06/2025 3:59 PM
Structure Therapeutics (1888886) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 3:15 PM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/22/2025 8:25 PM
Coll Crespo Blas (2037144) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/22/2025 8:25 PM
Hall Ashley (1801842) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 4:00 PM
Lin Xichen (1962926) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2025 4:00 PM
Ma Yingli (1963664) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2025 4:02 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G
08/14/2025 10:26 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
08/14/2025 7:46 AM
Deep Track Capital, LP (1856083) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
08/12/2025 10:20 AM
Structure Therapeutics (1888886) Subject
WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by
Form SCHEDULE 13G/A
08/06/2025 4:16 PM
Structure Therapeutics (1888886) Filer
Form S-3ASR
08/06/2025 3:28 PM
Structure Therapeutics (1888886) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/06/2025 11:14 AM
FMR LLC (315066) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
08/01/2025 8:34 AM
FMR LLC (315066) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 4:15 PM
Stevens Raymond C (1698149) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 4:15 PM
Structure Therapeutics (1888886) Issuer
Yoon Jun (1962414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 4:15 PM
Lin Xichen (1962926) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 4:15 PM
Ma Yingli (1963664) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2025 4:15 PM
Coll Crespo Blas (2037144) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 4:45 PM
Structure Therapeutics (1888886) Issuer
WELCH DANIEL G (1206199) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 4:45 PM
Structure Therapeutics (1888886) Issuer
TETLOW SHARON (1328565) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 4:45 PM
DOBMEIER ERIC (1202785) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 4:45 PM
Structure Therapeutics (1888886) Issuer
Waldstreicher Joanne (1962413) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 4:45 PM
LOVE TED W (1188919) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 4:45 PM
Russell Angus C. (1534002) Reporting
Structure Therapeutics (1888886) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/25/2025 3:15 PM
Structure Therapeutics (1888886) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025 7:42 AM
Deep Track Capital, LP (1856083) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
05/14/2025 11:32 AM
JANUS HENDERSON GROUP PLC (1274173) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
05/13/2025 10:32 AM
Capital Research Global Investors (1422848) Filed by
Structure Therapeutics (1888886) Subject
Form SCHEDULE 13G/A
05/08/2025 3:30 PM
Structure Therapeutics (1888886) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Structure Therapeutics SEC Filings - Frequently Asked Questions

Structure Therapeutics (GPCR) has submitted 185+ filings to the SEC since 2023. You can browse the complete history or filter by form type using the tools above.

Structure Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Structure Therapeutics's financial statements page.

The most recent filing was a Form ARS submitted on April 23, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:GPCR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners